Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Inclusion Criteria

• •Histologic proof of adenocarcinoma of the pancreas that is locally advanced and considered surgically not resectable or metastatic
• •Patients with or without prior treatment are eligible for treatment on protocol; prior treatment may have included one treatment course of chemo/RT and/ or one course of chemotherapy, but not two prior courses of chemotherapy;
• •Measurable disease
• •ECOG performance status of 0-1
• •Ability to sign an informed consent form indicating awareness of the investigational nature of this study, in keeping with the policies of the hospital
• •Patients may not be receiving any other concurrent chemotherapy, immunotherapy, or radiotherapy; the most recent treatment for pancreatic cancer, within the limitations of allowed prior therapy must be 28 days or longer prior to enrollment on study
• •Absolute granulocytes \> 1,500/mm\^3
• •Platelets \> 150,000/mm\^3
• •Serum bilirubin \< 1.5 mg/dl
• •Serum creatinine \< 1.5 mg/dl